Ayala Pharmaceuticals Inc Stock News

Zacks Investment Research lowered shares of Ayala Pharmaceuticals (NASDAQ:AYLA) from a buy rating to a hold rating in a report released on Tuesday morning, Zacks.com reports. According to Zacks, Ayala Pharmaceuticals Inc. is a clinical-stage oncology company. It focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. Ayala []

Jefferies Financial Group upgraded shares of Ayala Pharmaceuticals (NASDAQ:AYLA) from a hold rating to a buy rating in a report issued on Tuesday morning, Price Targets.com reports. They currently have $17.00 price objective on the stock, up from their prior price objective of $12.00. Jefferies Financial Group also issued estimates for Ayala Pharmaceuticals Q4 2021 []

Zacks Investment Research upgraded shares of Ayala Pharmaceuticals (NASDAQ:AYLA) from a hold rating to a buy rating in a research note published on Wednesday morning, Zacks.com reports. The firm currently has $11.00 target price on the stock. According to Zacks, Ayala Pharmaceuticals Inc. is a clinical-stage oncology company. It focused on developing and commercializing small []

Zacks Investment Research downgraded shares of Ayala Pharmaceuticals (NASDAQ:AYLA) from a buy rating to a hold rating in a research note issued to investors on Monday morning, Zacks.com reports. According to Zacks, Ayala Pharmaceuticals Inc. is a clinical-stage oncology company. It focused on developing and commercializing small molecule therapeutics for patients suffering from rare and []

Ayala Pharmaceuticals (NASDAQ:AYLA) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a note issued to investors on Thursday, Zacks.com reports. The brokerage currently has a $12.00 price target on the stock. Zacks Investment Researchs target price would indicate a potential upside of 19.76% from the companys previous close. []

The average of price targets set by Wall Street analysts indicates a potential upside of 115.8% in Ayala Pharmaceuticals, Inc. (AYLA). While the effectiveness of this highly sought-after metric is que

The average of price targets set by Wall Street analysts indicates a potential upside of 115.8% in Ayala Pharmaceuticals, Inc. (AYLA). While the effectiveness of this highly sought-after metric is que

Ayala Pharmaceuticals, Inc. (AYLA) delivered earnings and revenue surprises of 10.53% and -23.78%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for

Ayala Pharmaceuticals, Inc. (AYLA) delivered earnings and revenue surprises of 10.53% and -23.78%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for

- Presented Preliminary Clinical Data from 6mg Cohort of Phase 2 ACCURACY Trial of AL101 in R/M ACC Demonstrating 70% Disease Control Rate at ESMO 2021

REHOVOT, Israel and WILMINGTON, Del., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small mo

Ayala Pharmaceuticals, Inc. (AYLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ayala Pharmaceuticals Inc (NASDAQ: AYLA) announced new preliminary data from the 6mg cohort of its ongoing Phase 2 ACCURACY trial of AL101 in recurrent/metastatic (R/M) adenoid cystic carcinoma (AC

REHOVOT, Israel and WILMINGTON, Del., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small m

Ayala Pharmaceuticals, Inc. (AYLA) delivered earnings and revenue surprises of -19.05% and -25.61%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the